Reality Check on Pain Narcotic Opioid
Market access for pain narcotic opioid treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, around 43% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: A study by researchers at Johns Hopkins Bloomberg School of Public Health found that step therapy was rarely required for opioids, while prior authorization was applied to "only a minority" of covered opioids
- Key Findings: Many brand name products (Xtampza ER, Oxaydo) continue to enter this market despite the numerous generics.
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.